I.C.O.N. C.L.I.N.I.C.A.L.

C. O. N. N. E. C. T.

CONTACT DETAILS

Email ID:
Sobha.Jacob@iconplc.com
Phone #:
919.294.2237.
Address:
300 Research Dr.
Durham, NC.
27710

Icon is a pharmaceutical company that provides

clinical research services.

Our company was established in 1996. It’s

head-quarters are located in Dublin, Ireland.

R.E.S.E.A.R.C.H.
 ABOUT ICON
Icon is well-reputed for it’s trailblazing
contributions to the pharmaceutical world.
In the past 20 years, Icon has made significant
advancements in core laboratory technologies.
QUALITY MANAGEMENT SYSTEMS
Icon’s QMS, otherwise alluded to as, “quality
management systems” encompasses instruments
and apparatuses to guarantee that all services are
completed to the most ethical standard, adheres
to all pertinent regulatory obligations and meets
contractual requirements.
The QMS is largely contingent upon perpetual
development with current measurement of
performance procedures to regulate the success
of the QMS.
The order and interaction of each procedure
is explicitly demarcated. This is inclusive of
the process for regulation and the metrics for
determining overall efficiency.
The procedures have motion detectors and
effectively manages risks for project inspection at
any point in time. Overall, Icon’s QMS is designed
from the following chief characteristics: process,
compliance, quality assurance and risk.
MEDICAL IMAGING TECHNOLOGY
APPLIED INNOVATION
Icon utilizes cutting edge technology integrated
with market leading expertise and the most
efficient procedures to modernize and
restructure the management of pictures during
the process of clinical trials.
Furthermore, our company also provides
essential directions on FDA guidance document
input. Not to mention, this company has also
effectively distributed over 25 FDA approvals,
and their experts have the most involvement in
transporting medical imaging services.
TRANSFORMING CLINICAL TRIALS
IMPROVING PHARMA R&D EFFICIENCY
With growth cycles becoming too extensive,
experimental complications gradually augmenting,
and additonal analysis of the economic value of
new treatments, pharm R&D business prototypes
are under substantial pressure to make radical
progression in R&D productivity.
These impediments are due to an obsolete clinical
trial archetype. The conventional method inclusive of
three distinct, fixed experimental stages intended for
testing mass market medications is often not practical
in modern-day pharmaceutical market.
This technique is devoid of the tractability, logical
power, and rapidity required to make further
advancements to intricate and multifaceted new
treatments. Not to mention, this traditional approach
also fails to meet the standards of a niche audience,
especially that of a smaller and more diverse patient
population.